Cumulative effects of therapies on disability in relapsing multiple sclerosis

被引:11
|
作者
Rollot, Fabien [1 ,2 ,3 ,4 ,5 ]
Casey, Romain [1 ,2 ,3 ,4 ,5 ]
Leray, Emmanuelle [6 ,7 ]
Debouverie, Marc [8 ,9 ]
Edan, Gilles [7 ,10 ]
Wiertlewski, Sandrine [11 ,12 ]
Vukusic, Sandra [1 ,2 ,3 ,4 ,5 ]
Laplaud, David-Axel [11 ,12 ,13 ]
机构
[1] Univ Claude Bernard Lyon 1, Univ Lyon, Lyon, France
[2] Hosp Civils Lyon, Serv Neurol Sclerose Plaques Pathol Myeline & Neu, Bron, France
[3] Ctr Rech Neurosci Lyon, INSERM 1028, Observ Francais Sclerose Plaques, Lyon, France
[4] CNRS, UMR 5292, Lyon, France
[5] EUGENE DEVIC EDMUS Fdn, Bron, France
[6] Univ Rennes EHESP, REPERES EA 7449, Rennes, France
[7] CHU Rennes, CIC P 1414, Rennes, France
[8] CHU Nancy, Dept Neurol, Nancy, France
[9] Univ Lorraine, EA APEMAC 4360, Nancy, France
[10] CHU Rennes, Dept Neurol, Rennes, France
[11] CHU Nantes, Dept Neurol, Nantes, France
[12] CHU Nantes, CIC Inserm 1415, Nantes, France
[13] Ctr Rech Transplantat & Immunol, Inserm, U1064, Nantes, France
关键词
Multiple sclerosis; treatment response; cumulative effect; long-term observational study; PLACEBO-CONTROLLED TRIAL; DISEASE-MODIFYING DRUG; INTERFERON BETA-1A; NATURAL-HISTORY; DOUBLE-BLIND; PROGRESSION; EXPOSURE; BENZODIAZEPINES; ASSOCIATION; FINGOLIMOD;
D O I
10.1177/1352458520980366
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Long-term effectiveness of treatment remains a key question in multiple sclerosis (MS) and the cumulative effects of past treatment have not been investigated so far. Objective: Explore the relationship between treatment exposure and disability risk in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: A total of 2285 adult patients from the French nationwide cohort were included. Outcomes were irreversible EDSS4, and conversion to secondary progression of multiple sclerosis (SPMS). Associations between treatments and risk of disability were assessed using a novel weighted cumulative exposure model, assuming a 3-year lag to account for reverse causality. This flexible approach accounts for past exposure in a multivariate Cox proportional hazards model by computing a weight function. Results: At baseline, mean +/- standard deviation age of patients was 33.4 +/- 8.9 years and 75.0% were women. A 15-year continuous treatment starting 20 years ago was associated with a decrease in risk of 26% for irreversible EDSS4, and 34% for SPMS compared to a 5-year treatment starting 10 years ago. The risk of disability decreased with increasing duration of exposure to disease-modifying treatment (DMT). Conclusion: Long-term use of treatments in RRMS has a stronger beneficial cumulative impact than only early uses and delays the occurrence of moderate disability and conversion to SPMS.
引用
收藏
页码:1760 / 1770
页数:11
相关论文
共 50 条
  • [1] Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis
    Rollot, F.
    Casey, R.
    Debouverie, M.
    Edan, G.
    Wiertlewski, S.
    Leray, E.
    Vukusic, S.
    Laplaud, D-A
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 344 - 345
  • [2] Disease modifying therapies for relapsing multiple sclerosis
    Wingerchuk, Dean M.
    Weinshenker, Brian G.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [3] Emerging Therapies ford Relapsing Multiple Sclerosis
    Cohen, Jeffrey A.
    ARCHIVES OF NEUROLOGY, 2009, 66 (07) : 821 - 828
  • [4] Advances in oral immunomodulating therapies in relapsing multiple sclerosis
    Derfuss, Tobias
    Mehling, Matthias
    Papadopoulou, Athina
    Bar-Or, Amit
    Cohen, Jeffrey A.
    Kappos, Ludwig
    LANCET NEUROLOGY, 2020, 19 (04): : 336 - 347
  • [5] PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Somilo, O., V
    Kalbus, O., I
    Makarov, S. O.
    Sorokin, A. V.
    Shastun, N. P.
    WORLD OF MEDICINE AND BIOLOGY, 2023, 84 (02): : 147 - 152
  • [6] Bifactor structure of clinical disability in relapsing multiple sclerosis
    Chamot, Eric
    Kister, Ilya
    Cutter, Garry R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (02) : 176 - 185
  • [7] Predicting disability worsening in relapsing and progressive multiple sclerosis
    Simmons, Sarah B.
    Schippling, Sven
    Giovannoni, Gavin
    Ontaneda, Daniel
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (03) : 312 - 321
  • [8] Prognostic factors of disability in relapsing remitting multiple sclerosis
    Briggs, Farren B. S.
    Thompson, Nicolas R.
    Conway, Devon S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 : 9 - 16
  • [9] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
    Marriott, James J.
    O'Connor, Paul W.
    REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 179 - 188
  • [10] Disability trajectories in relapsing-remitting multiple sclerosis
    Uher, T.
    Horakova, D.
    Havrdova, E. Kubala
    Izquierdo, G.
    Eichau, S.
    Patti, F.
    Prat, A. P.
    Girard, M.
    Duquette, P.
    Grammond, P.
    Onofrj, M.
    Lugaresi, A. L.
    Bergamaschi, R.
    Ozakbas, S.
    Grand'Maison, F.
    Hupperts, R.
    Sola, P.
    Ferraro, D.
    Sa, M. J.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 813 - 814